Timothy Coughlin, Director at Travere Therapeutics, Inc. (TVTX), sold 3,250 shares at $43.49 ($141K) on 2026-05-15, disclosed to the SEC on 2026-05-19.
Scheduled sale ($141k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| LIFE | BUY | 2024-06-03 | $88K | — | Filing → |
| FATE | SELL | 2022-06-06 | $33K | — | Filing → |